Mantoan Ritter, Laura, Annear, Nicholas M. P., Baple, Emma L., Ben-Chaabane, Leila Y., Bodi, Istvan, Brosson, Lauren, Cadwgan, Jill E., Coslett, Bryn, Crosby, Andrew H., Davies, D. Mark, Daykin, Nicola, Dedeurwaerdere, Stefanie, Dühring Fenger, Christina, Dunlop, Elaine A.  ORCID: https://orcid.org/0000-0002-9209-7561, Elmslie, Frances V., Girodengo, Marie, Hambleton, Sophie, Jansen, Anna C., Johnson, Simon R., Kearley, Kelly C., Kingswood, John C., Laaniste, Liisi, Lachlan, Katherine, Latchford, Andrew, Madsen, Ralitsa R., Mansour, Sahar, Mihaylov, Simeon R., Muhammed, Louwai, Oliver, Claire, Pepper, Tom, Rawlins, Lettie E., Schim van der Loeff, Ina, Siddiqui, Ata, Takhar, Pooja, Tatton-Brown, Katrina, Tee, Andrew R. ORCID: https://orcid.org/0000-0002-5577-4631, Tibarewal, Priyanka, Tye, Charlotte, Ultanir, Sila K., Vanhaesebroeck, Bart, Zare, Benjamin, Pal, Deb K. and Bateman, Joseph M.
2025.
mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node.
Orphanet Journal of Rare Diseases
20
(256)
10.1186/s13023-025-03740-1
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (5MB) | Preview |
Abstract
Mechanistic target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates key cellular processes including cell growth, autophagy and metabolism. Hyperactivation of the mTOR pathway causes a group of rare and ultrarare genetic diseases. mTOR pathway diseases have diverse clinical manifestations that are managed by distinct medical disciplines but share a common underlying molecular basis. There is a now a deep understanding of the molecular underpinning that regulates the mTOR pathway but effective treatments for most mTOR pathway diseases are lacking. Translating scientific knowledge into clinical applications to benefit the unmet clinical needs of patients is a major challenge common to many rare diseases. In this article we expound how mTOR pathway diseases provide an opportunity to coordinate basic and translational disease research across the group, together with industry, medical research foundations, charities and patient groups, by pooling expertise and driving progress to benefit patients. We outline the germline and somatic mutations in the mTOR pathway that cause rare diseases and summarise the prevalence, genetic basis, clinical manifestations, pathophysiology and current treatments for each disease in this group. We describe the challenges and opportunities for progress in elucidating the underlying mechanisms, improving diagnosis and prognosis, as well as the development and approval of new therapies for mTOR pathway diseases. We illustrate the crucial role of patient public involvement and engagement in rare disease and mTOR pathway disease research. Finally, we explain how the mTOR Pathway Diseases node, part of the Research Disease Research UK Platform, will address these challenges to improve the understanding, diagnosis and treatment of mTOR pathway diseases.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | Published |
| Schools: | Schools > Medicine |
| Publisher: | BioMed Central |
| ISSN: | 1750-1172 |
| Date of First Compliant Deposit: | 27 May 2025 |
| Date of Acceptance: | 16 April 2025 |
| Last Modified: | 30 May 2025 09:45 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/178537 |
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric